2019
Multicenter phase II trial of RRx-001 in previously treated SCLC.
Morgensztern D, Rose M, Morris J, Ma P, Brzezniak C, Zeman K, Padmanabhan A, Hirth J, Spira A, Wong E, Padda S, Waqar S. Multicenter phase II trial of RRx-001 in previously treated SCLC. Journal Of Clinical Oncology 2019, 37: e20104-e20104. DOI: 10.1200/jco.2019.37.15_suppl.e20104.Peer-Reviewed Original ResearchSmall cell lung cancerRRx-001Partial responseStable diseaseOverall survivalPrior linesCommon treatment-emergent adverse eventsSingle-arm phase II studyArm phase II studyMulticenter phase II trialTreatment-emergent adverse eventsPhase II studyPhase II trialPlatinum-resistant diseaseCell lung cancerOverall response rateTreat populationII trialPrimary endpointAdverse eventsEtoposide chemotherapyII studyComplete responsePlatinum therapyLung cancer
2009
Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC)
Galper S, Deshpande H, Rose M, Decker R. Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC). Journal Of Clinical Oncology 2009, 27: e17030-e17030. DOI: 10.1200/jco.2009.27.15_suppl.e17030.Peer-Reviewed Original ResearchOverall survivalCHRT groupLate toxicityMucosal toxicityAcute mucosal toxicityHigher daily doseTumor registry dataOverall treatment timeDefinitive chemoradiationAcute mucositisConcurrent chemoradiationAdvanced headCompliant patientsLess weight lossRandomized studySkin necrosisCisplatin chemoradiationDaily doseDistant metastasisPatient chartsNeck cancerAltered fractionationRadiation fractionationRegistry dataNonsignificant decrease